Oppenheimer reiterates Outperform on Relay Therapeutics (RLAY) as zovegalisib shows 11.1-month PFS

March 16, 2026 4:37 PM

Oppenheimer analyst Matt Biegler reiterated an Outperform rating and $14.00 price target on Relay Therapeutics (NASDAQ: RLAY)The analyst commented, "Relay ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found